ICS/formoterol in the management of asthma in the clinical practice of pulmonologists: an international survey on GINA strategy.

ABSTRACT:

Background

The treatment with short-acting beta-2 agonists (SABA) alone is no longer recommended due to safety issues. Instead, the current Global Initiative for Asthma (GINA) Report recommends the use of the combination of inhaled corticosteroids (ICS) with the rapid/long-acting beta-2 agonist formoterol, although the use in steps 1 and 2 is still off-label in the EU and in many countries. It is important to understand clinicians' knowledge and opinions on the issue with the ultimate goal to encourage the implementation of the new approach in clinical practice.

Methods

We performed an international survey, directed to pulmonologists interested in the management of patients with asthma.

Results

Most participants reported that SABA alone should not be used in GINA Step

SUBMITTER: Cruz AA 

PROVIDER: S-EPMC7844897 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature